Zanzalintinib is named as an intervention in 14 current clinical trials in our USA, UK, China and Ireland registers. 9 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Exelixis (11). The most-studied condition is Renal Cell Carcinoma.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Renal Cell Carcinoma | 3 |
| Renal Cell Carcinoma (RCC) | 2 |
| Solid Tumor | 2 |
| Colorectal Cancer | 2 |
| Carcinoma, Renal Cell | 1 |
| Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 1 |
| Urothelial Carcinoma (UC) | 1 |
| Pancreatic Neuroendocrine Tumor (pNET) | 1 |
| Extra-Pancreatic Neuroendocrine Tumor (epNET) | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Advanced Solid Tumor | 1 |
| Metastatic Solid Tumor | 1 |
| Immune Sensitive Tumor | 1 |
| Hepatic Impairment | 1 |
| Moderate Hepatic Impairment | 1 |
| Meningioma | 1 |
| Cancer | 1 |
| Pancreatic Neuroendocrine Tumors (pNET) | 1 |
| Extra-Pancreatic NET (epNET) | 1 |
| Non-Clear Cell Renal Cell Carcinoma | 1 |
| Neoplasm Malignant | 1 |
| Hormone Receptor Positive Breast Carcinoma | 1 |
| Metastatic Castration-resistant Prostate Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Exelixis | 11 |
| Merck Sharp & Dohme LLC | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 14 | 9 |
| Clinical trials in UK | 9 | 5 |
| Clinical trials in China | 2 | 2 |
| Clinical trials in Ireland | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
14 current trials in our USA, UK, China and Ireland registers name Zanzalintinib (also registered as XL092) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 9 of the 14 trials are recruiting: 9 with sites in USA, 5 with sites in UK, 2 with sites in China and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Exelixis (11) and Merck Sharp & Dohme LLC (3). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zanzalintinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zanzalintinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zanzalintinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.